Drug-eluting Balloon Catheters Market Size, Trends, Growth, Opportunities (2022-2029) | Medtronic, BD, and B. Braun SE

The drug-eluting balloon catheters market was valued at USD 529.4 million in 2021 and is projected to grow from USD 615.2 million in 2022 to USD 1,119.4 million by 2029, recording a CAGR of 8.9% during the forecast period (2022-2029).

The Drug-eluting Balloon Catheters Market is revolutionizing cardiovascular care by offering advanced treatment options for Peripheral Artery Disease (PAD). These devices deliver therapeutic drugs to target sites, minimizing the risk of restenosis and improving patient outcomes. Recent innovations and clinical trials are shaping the market's trajectory, making it a critical area of focus in global healthcare.

𝗗𝗶𝘀𝗰𝗼𝘃𝗲𝗿 𝗪𝗵𝗮𝘁 𝗬𝗼𝘂'𝗿𝗲 𝗠𝗶𝘀𝘀𝗶𝗻𝗴: 𝗚𝗲𝘁 𝗮 𝗙𝗿𝗲𝗲 𝗥𝗲𝗽𝗼𝗿𝘁 (𝗣𝗗𝗙) 𝗦𝗮𝗺𝗽𝗹𝗲: https://www.fortunebusinessinsights.com/enquiry/sample/drug-eluting-balloon-catheters-market-107028

𝗞𝗲𝘆 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁

In August 2022, BD announced the initiation of a first-in-human precision trial for its peripheral sirolimus drug-coated balloon (DCB). This groundbreaking trial aims to evaluate the safety and efficacy of sirolimus as a potential treatment for PAD. The results of this study could pave the way for sirolimus DCBs to become a new standard of care for patients suffering from this condition.

𝗧𝗼𝗽 𝗖𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗗𝗿𝘂𝗴-𝗲𝗹𝘂𝘁𝗶𝗻𝗴 𝗕𝗮𝗹𝗹𝗼𝗼𝗻 𝗖𝗮𝘁𝗵𝗲𝘁𝗲𝗿𝘀 𝗠𝗮𝗿𝗸𝗲𝘁

• Medtronic (Ireland)
• Koninklijke Philips N.V. (Netherlands)
• Boston Scientific Corporation (U.S.)
• BD (U.S.)
• B. Braun SE (Germany)
• Meril Life Sciences Pvt. Ltd. (India)
• BIOTRONIK (Germany)
• Cordis (U.S.)
• MicroPort Medical (Group) Co., Ltd. (China)

𝗠𝗮𝗿𝗸𝗲𝘁 𝗗𝗿𝗶𝘃𝗲𝗿𝘀

𝗥𝗶𝘀𝗶𝗻𝗴 𝗣𝗿𝗲𝘃𝗮𝗹𝗲𝗻𝗰𝗲 𝗼𝗳 𝗣𝗲𝗿𝗶𝗽𝗵𝗲𝗿𝗮𝗹 𝗔𝗿𝘁𝗲𝗿𝘆 𝗗𝗶𝘀𝗲𝗮𝘀𝗲

The increasing incidence of PAD, a condition characterized by reduced blood flow to the extremities, is a major driver for the market. A growing aging population and a rise in diabetes and smoking-related PAD cases are fueling demand for advanced treatment options like drug-eluting balloon catheters.

𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗺𝗲𝗻𝘁𝘀

Innovations in drug-coating techniques and delivery systems are enhancing the efficacy and safety of these devices. The development of sirolimus-coated balloons, as seen in BD's trials, highlights the potential for improved long-term outcomes compared to traditional treatments.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀

𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗖𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀

Stringent regulatory requirements for drug-coated devices can delay product launches and impact market growth. Manufacturers must conduct extensive clinical trials to demonstrate safety and efficacy.

𝗖𝗼𝘀𝘁 𝗖𝗼𝗻𝘀𝘁𝗿𝗮𝗶𝗻𝘁𝘀

High costs associated with drug-eluting balloon catheters may limit adoption in regions with constrained healthcare budgets. Efforts to develop cost-effective solutions are crucial for market expansion.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲

The comprehensive Drug-eluting Balloon Catheters Market report provides insights into key industry trends, competitive dynamics, and market segmentation. It covers product innovations, clinical trial developments, and regional growth patterns.

𝗙𝗼𝗿 𝗙𝘂𝗹𝗹 𝗥𝗲𝗽𝗼𝗿𝘁 𝗖𝗼𝘃𝗲𝗿𝗮𝗴𝗲 𝗩𝗶𝘀𝗶𝘁:https://www.fortunebusinessinsights.com/drug-eluting-balloon-catheters-market-107028

𝗠𝗮𝗿𝗸𝗲𝘁 𝗖𝗼𝗺𝗽𝗲𝘁𝗶𝘁𝗶𝘃𝗲 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲

Leading companies such as Medtronic, BD, and Boston Scientific Corporation are driving innovation through robust R&D efforts. The focus on developing drug-coated balloon catheters that offer superior clinical outcomes is intensifying competition in the market. Collaborations and strategic partnerships further strengthen the industry's competitive edge.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗲𝗴𝗺𝗲𝗻𝘁𝘀

𝗣𝗮𝗰𝗹𝗶𝘁𝗮𝘅𝗲𝗹 𝗦𝗲𝗴𝗺𝗲𝗻𝘁 𝗟𝗲𝗮𝗱𝘀 𝘁𝗵𝗲 𝗠𝗮𝗿𝗸𝗲𝘁

By drug type, the paclitaxel segment dominates the market due to its proven efficacy in preventing restenosis. Ongoing research into alternative drugs like sirolimus is expected to diversify the product landscape and enhance treatment options.

𝗠𝗮𝗿𝗸𝗲𝘁 𝗥𝗲𝗴𝗶𝗼𝗻𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀

North America and Europe are the largest markets for drug-eluting balloon catheters, driven by advanced healthcare systems and high prevalence of PAD. The Asia-Pacific region is poised for significant growth, fueled by increasing healthcare investments, improving infrastructure, and rising awareness of cardiovascular care.

𝗙𝘂𝘁𝘂𝗿𝗲 𝗠𝗮𝗿𝗸𝗲𝘁 𝗦𝗰𝗼𝗽𝗲

• Introduction of sirolimus-based DCBs to expand treatment options and improve clinical outcomes.
• Growth in minimally invasive procedures driving demand for advanced catheter-based solutions.
• Emergence of AI-driven imaging technologies for precision placement of drug-eluting balloon catheters.
• Increased focus on cost-effective innovations to ensure widespread adoption.

𝗖𝗼𝗻𝗰𝗹𝘂𝘀𝗶𝗼𝗻

The Drug-eluting Balloon Catheters Market is at the forefront of transforming cardiovascular care, particularly for PAD patients. Innovations like BD's sirolimus DCB trials are setting new benchmarks in treatment efficacy and safety. As healthcare systems worldwide prioritize advanced therapeutic solutions, the market is poised for sustained growth and development.

For a detailed analysis, visit the Drug-eluting Balloon Catheters Market Report.

𝗖𝘂𝘀𝘁𝗼𝗺𝗶𝘇𝗲 𝗧𝗵𝗶𝘀 𝗥𝗲𝗽𝗼𝗿𝘁 𝗔𝗰𝗰𝗼𝗿𝗱𝗶𝗻𝗴 𝗧𝗼 𝗬𝗼𝘂𝗿 𝗖𝗼𝗻𝘃𝗲𝗻𝗶𝗲𝗻𝗰𝗲: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/drug-eluting-balloon-catheters-market-107028

𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀:
Fortune Business Insights™ Pvt. Ltd.
9th Floor, Icon Tower,
Baner, Pune-411045,
Maharashtra, India.
Phone:
U.S.:+1 833 909 2966 (Toll-Free)
U.K.: +44 808 502 0280 (Toll-Free)
APAC +91 744 740 1245
Email: sales@fortunebusinessinsights.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

This release was published on openPR.